These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23187882)

  • 1. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.
    Shiraishi K; Mimura K; Izawa S; Inoue A; Shiba S; Maruyama T; Watanabe M; Kawaguchi Y; Inoue M; Fujii H; Kono K
    Gastric Cancer; 2013 Oct; 16(4):571-80. PubMed ID: 23187882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
    Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
    Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
    Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
    Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
    Barok M; Tanner M; Köninki K; Isola J
    Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
    Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
    Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
    Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
    Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.
    Kostyal D; Welt RS; Danko J; Shay T; Lanning C; Horton K; Welt S
    Med Oncol; 2012 Sep; 29(3):1486-94. PubMed ID: 21769502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
    Deng X; Fogh L; Lademann U; Jensen V; Stenvang J; Yang H; Brünner N; Schrohl AS
    Tumour Biol; 2013 Apr; 34(2):1161-70. PubMed ID: 23334956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
    Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
    Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
    Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.